Summary of COVID-19 zunsemetinib studies

1. Gan et al., A Double-blind, Randomized, Controlled Trial of ATI-450 in Patients With Moderate-severe COVID-19

20 patient zunsemetinib late treatment RCT: no change in mortality (p=1) and 25% higher progression (p=1).
RCT 20 hospitalized patients showing no significant difference in outcomes with ATI-450 (zunsemetinib).
Jun 2025, NCT04481685, https://clinicaltrials.gov/study/NCT04481685, https://c19p.org/gan